Skip to content

ADMA Biologics ADMA Current ratio

Current ratio at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
14.1×+3.9×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
7.6×-0.7×
Zymeworks logo
ZymeworksZYME
10.8×+6.1×
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
3.2×-2.8×
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
32.6×+16.8×
Quest Diagnostics logo
Quest DiagnosticsDGX
1.2×-0.3×

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×

Where this comes from

Calculated from ADMA Biologics’s reported figures.

Based on the most recent quarter.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's current ratio?
ADMA Biologics (ADMA) reported current ratio of 7× in Q1 2026.
How has ADMA Biologics's current ratio changed year-over-year?
ADMA Biologics's current ratio increased by 5.7% year-over-year, from 6.6× to 7×.
What is the long-term trend for ADMA Biologics's current ratio?
Over 5 years (2020 to 2025), ADMA Biologics's current ratio has grown at a -2.7% compound annual growth rate (CAGR), from 7.7× to 6.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.